Nick Pinero’s Post

Jeanne Hecht, CEO and Chairwoman of Lexitas Pharma Services and esteemed member of 20/20 Onsite's Industry and Scientific Advisory Board, recently participated in a dynamic panel exploring the latest market trends for CROs. The discussion highlighted key topics such as the importance of specialization, ensuring diversity in clinical trials, and leveraging AI to enhance efficiency. The panel also addressed demands from pharmaceutical companies for expedited and high-quality trials. Congratulations, Jeanne, on your contributions to this important conversation. We look forward to hearing more of your insights and advancements. Dive into the key takeaways from the session:https://hubs.ly/Q02K_1NQ0 #CROs #LifeScience #TA #AI #ClinicalResearch

💡We are delighted to share the highlight impressions of the first AI Forum from Pharma to Pharma. 💡 It was a great experience that provided over 70 participants with insights and knowledge from presenters working in pharma. With over 50 companies in attendance, this event marked the beginning of an exciting new chapter in the evolving world of AI in pharma. Together, we created a valuable new platform for discussing topics related to AI in the pharmaceutical industry. This AI - Forum from June 11th, 2024 marks the start of an ongoing exchange. Check out the highlight video to get insights from the forum. Stay tuned for the next AI events to come. #artificialintelligence #pharma #shqa #ffi #aiforum

The landscape of #artificialintelligence is undergoing a seismic shift. The recent AI Forum in Switzerland by shqa swiss health quality association and FFI Ventures, held on June 11th, 2024, brought together over 70 participants from more than 50 companies to explore this transformative era. This gathering wasn't just about discussing AI. It was about navigating the revolutionary impact of generative AI in pharma. Presenters from the industry shared initial insights, illuminating how generative AI has an impact in Pharma and to its stakeholders. The forum marked the dawn of a new era, where AI isn't just a tool, but a collaborative partner in pharmaceutical innovation. We've only scratched the surface of generative AI's potential in pharma. This event is the first step in an ongoing journey of discovery and collaboration. Stay connected for future AI events as we continue to explore this rapidly evolving field. The future of pharma is being rewritten by AI, and we're at the forefront of this exciting transformation. Thanks to @shqa providing such a great platform to discuss the disruptive nature of #genAI.

👀 Read our new article in collaboration with Nature Portfolio: “How to turn a data maze into a goldmine through AI drug positioning” This piece interviews Servier’s Samer El Bawab, as well as Owkin voices Jonas Béal and Anna Gogleva, to explain the science behind our AI drug positioning engine DrugMatch. In it we explores how we use knowledge graphs, the importance of subgroup positioning and what the pharmaceutical industry thinks. Read the article here https://lnkd.in/eGhQgD9r

Standigm’s CEO Dr. YounSung Choo, shared his insights at the AI Pharma Korea Conference 2023 on the creation of an innovation ecosystem to accelerate AI-driven drug discovery. From his speech, Dr. Choo suggested strengthening open innovation between AI companies and pharmaceutical companies, expanding national projects to develop AI drug discovery, establishing and integrating data management organization, and establishing new data utilization guidelines. For more information about his speech, please visit https://lnkd.in/g-HjFRUN #standigm #AIPharmaKoreaConference2023 #AIDrugdiscovery

Interesting article on Gen AI in Pharma from Mckinsey. Generative AI in the pharmaceutical industry | McKinsey. https://lnkd.in/ehKysxdf Highlights the really big customer insight opportunity in Medical that we at KAI Conversations are already exploiting alongside commercial optimisation with a number of Top 20 global pharma businesses. The hype vs reality pieces highlights the real practical difficulties and why using GenAI alone isn't enough.

A fascinating discussion on the implications of AI in healthcare with Neil Rotherham, Rich Cooper and Julian Minett. 💡 #healthcare #pharmatech #AI #bigdata #medicinesinformation

At our recent panel session, we had the pleasure of hosting industry experts, including Paul Agapow, director at GSK, to discuss applying AI-derived insights to improve healthcare outcomes. 💡 Coming from a leading pharmaceutical company, Agapow provided a valuable perspective on validating the clinical utility of medical AI algorithms. He highlighted the importance of measuring outcomes that clearly improve patient care and quality of life, rather than just technical metrics. While acknowledging AI's potential, Agapow stressed that proving its value requires methodically validating real-world impacts using patient-centric data. Watch the full video here: https://lnkd.in/e3mDvZtq #HealthcareAI #PatientCentric #bioXcelerateAI #GSK #ClinicalOutcomes #AIMedicine #InnovationInHealthcare 

Our Chief Medical Officer Sheuli Porkess was privileged to contribute to this fantastic discussion, facilitated by John Rountree of Novasecta last month. Along with senior executives in the biotech and pharmaceutical sectors, the discussion explored the potential for AI to support Research and Development of new pharmaceutical interventions. A key area where the potential of AI has yet to be fully realised is the opportunity to help increase diversity of participation in clinical trials through identification of patient populations and cohorts that have high risk of disease progression, reflecting key co-morbidities. This is becoming possible, as it is across all the functions of pharmaceutical R&D, informed by real world patient, and health economic, data. A key takeaway from the discussion was that harnessing of AI's full potential requires an increasingly conscious cross-functional, multi-diciplinary approach to make this a reality - which Precisia Clinical Risk Analytics stands ready to support.

In March 2024, John Rountree, Managing Director of Novasecta, facilitated Chatham-House-Rules discussion for senior executives in the biotech and pharmaceutical sectors, focusing on how firms can make the most of AI for their R&D efforts. This report summarises insights from the workshop. With transparency, realism, and a truly multi-disciplinary and cross-functional mindset, AI has great potential in pharmaceutical R&D. The best is yet to come. Read more here: https://lnkd.in/e4su9hzh